Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Mollie Leoni, ...

I am a never-smoker who was diagnosed with Stage 1 Non-Small Cell Lung Cancer ... I’m 58 and I was diagnosed with small cell carcinoma in February 2024. Margie M. September 2024 will be my 5 year ...

The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, ...

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Hanx Biopharmaceuticals chairman Dr Faming Zhang said: "We are thrilled to see the first patient entered into a clinical ...